Posted on October 17, 2017 by Sitemaster
We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, outcome, PSMA, survival | 5 Comments »
Posted on October 16, 2017 by Sitemaster
On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, castration-resistant, deprivation, mCRPC, metastatic, SPARE, trial | Leave a comment »
Posted on September 15, 2017 by Sitemaster
Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian, mCRPC, Nordic, PROSPECT, Prostvac, trial | 4 Comments »
Posted on September 15, 2017 by Sitemaster
Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, dose, Jevtana, lower, mCRPC | Leave a comment »
Posted on September 11, 2017 by Sitemaster
Ipatasterib is a new type of drug that can be used to block the so-called PI3K/Akt signaling pathway, which is often highly activated in men with metastatic, castration-resistant prostate cancer (mCRPC). … REAF MORE…
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasterib, mCRPC, metastatic, Phase III, trial | Leave a comment »
Posted on September 3, 2017 by Sitemaster
So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: hormone-resistant, hormone-sensistive, latitude, mCRPC, metastatic, mHSPC, STAMPEDE, Treatment | Leave a comment »
Posted on June 28, 2017 by Sitemaster
The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: advanced, ASCO, castration-resistant, genomic, mCRPC, metastatic, sequencing | Leave a comment »
